Manuscript citation: Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Krämer A, Schwalm MP, Lattal NM, Elson L, Chatterjee D, Mathea S, Hanke T, Leschziner AE, Reck-Peterson SL, Knapp S Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2. Science Advances 11(23). doi: 10.1126/sciadv.adt2050 License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Protocol status: WorkingWe use this protocol and it's working
Created: December 10, 2024
Last Modified: June 06, 2025
Protocol Integer ID: 114635
Keywords: LRRK2, motility assay, kinesin, imaging, single-molecule, ASAPCRN, lrrk2rckw single molecule kinesin motility assay, single molecule kinesin motility assays-2024 this protocol, single molecule kinesin motility assays-2024, single molecule kinesin motility assay, lrrk2rckw, assay
Funders Acknowledgements:ASAP
Grant ID: ASAP-000519